FoRx Therapeutics
  • Home
  • About us
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
    • Founders
  • Science
    • Pipeline
    • Background
  • News & Events
  • Careers
  • Contact
Select Page
FoRx Therapeutics AG Raises EUR 10 Million Seed Round  First Company to Develop a Pipeline of Drugs Targeting DNA Replication Stress for Cancer

FoRx Therapeutics AG Raises EUR 10 Million Seed Round
First Company to Develop a Pipeline of Drugs Targeting DNA Replication Stress for Cancer

Apr 22, 2020

Back to news FoRx Therapeutics AG Raises EUR 10 Million Seed Round First Company to Develop a Pipeline of Drugs Targeting DNA Replication Stress for Cancer Seasoned Biotech Executive Colin Goddard Joins as Executive Chairman Basel, Switzerland, 22 April, 2020 – FoRx...

News Archive

  • FoRx Therapeutics AG appoints Jens Würthner as Chief Medical Officer
  • Michael Kauffman appointed as Chairman of the Board of FoRx Therapeutics AG
  • FoRx Therapeutics Announces Development Candidate Nomination of Potential Best-in-Class PARG Inhibitor FORX-428
  • FoRx Therapeutics AG appoints Frank Zenke as Chief Scientific Officer
  • FoRx Therapeutics AG appoints Tarig Bashir as Chief Executive Officer
Privacy Policy | Imprint
© 2024 FoRx Therapeutics AG. All Rights Reserved